. 2018 Mar 8;9(7):1165–1172. doi: 10.7150/jca.23606

Table 2.

The difference in median values between benign ovarian masses and early-or advanced-stage EOC according to laboratory variables

	Benign ovarian mass, median (IQR) (n=261)	EOC, median (IQR)		P value
	Benign ovarian mass, median (IQR) (n=261)	Stage I-II (n=110)	Stage III-IV (n=119)	P value
Age (years)	35.0 (21.0)^a	51.0 (14.0)^b	57.0 (15.5)^c	<0.001
WBC (per µL)	6220.0 (2350.0)^a	6215.0 (2600.0)^a	6840.0 (3090.0)^b	<0.001
Hemoglobin (g/dL)	13.0 (1.4)^a	12.6 (1.5)^b	12.3 (2.0)^b	<0.001
Platelets (×10³/µL)	253.0 (75.0)^a	271.5 (95.0)^a	328.0 (152.5)^b	<0.001
CA125 (unit/mL)	19.0 (21.0)^a	52.7 (227.9)^b	471.6 (751.2)^c	<0.001
NLR	1.9 (1.1)^a	2.4 (1.7)^b	3.5 (3.0)^c	<0.001
PLR	136.1 (64.2)^a	163.4 (93.1)^b	234.3 (195.0)^c	<0.001
LMR	5.4 (2.9)^a	4.8 (3.1)^b	3.2 (2.6)^c	<0.001

Medians with the same letter (superscript) are not significantly different. P-values for comparisons of medians were obtained using the Kruskal-Wallis test. A post-hoc test (Bonferroni) was applied with pairwise comparison between medians.

EOC, epithelial ovarian cancer; IQR, interquartile range; WBC, white blood cell; CA125, cancer antigen 125; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; LMR, lymphocyte-monocyte ratio